Heparin-induced Thrombocytopenia Market Report 2032: Epidemiology Data, Therapies, Latest Approvals by DelveInsight

A single therapy, VLX-1005 (Veralox Therapeutics), is being investigated for treating heparin-induced thrombocytopenia.

LAS VEGAS, NEVADA, UNITED STATES, March 27, 2024 /EINPresswire.com/ -- DelveInsight’s “Heparin-induced Thrombocytopenia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Heparin-induced Thrombocytopenia, historical and forecasted epidemiology as well as the Heparin-induced Thrombocytopenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Heparin-induced Thrombocytopenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Heparin-induced Thrombocytopenia Market Forecast

Some of the key facts of the Heparin-induced Thrombocytopenia Market Report:

The Heparin-induced Thrombocytopenia market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

Key Heparin-induced Thrombocytopenia Companies: Veralox Therapeutics, Sandoz, Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Fresenius Kabi AG, Dr. Reddy's Laboratories Ltd., Amphastar Pharmaceuticals Inc., Aspen Pharmacare Holdings Limited, LEO Pharma A/S, Merck KGaA, and others

Key Heparin-induced Thrombocytopenia Therapies: ANGIOMAX, Argatroban, and others.

In 2022, there were a total of ~111,000 incident cases of Heparin-Induced Thrombocytopenia (HIT), which is expected to increase by 2032 in the United States.

In 2022, the total cases of Thrombosis in Heparin Induced Thrombocytopenia (HIT) in 7MM were ~106,000 cases.

Heparin-induced Thrombocytopenia (HIT) is a complex and intriguing immunological syndrome, often not fully understood. It represents a severe complication that can manifest in patients exposed to any form or dosage of heparin products. Despite its common use in preventing blood clots, heparin can paradoxically trigger the immune system to induce both blood clots and thrombocytopenia, defining HIT. This disorder is marked by a reduction in platelet counts and a hypercoagulable state.

In HIT, platelet-activating antibodies recognize multimolecular complexes bound to unfractionated heparin or low-molecular-weight heparin. Patients typically exhibit mild thrombocytopenia or a 50% decrease in platelet count from baseline. Thrombotic complications, known as heparin-induced thrombocytopenia with thrombosis, develop in 20–50% of patients and can affect both arterial and venous systems, persisting even after discontinuation of heparin.

Diagnosis of HIT usually involves clinical assessment using the 4Ts scoring system, with a score of 4 indicating a high likelihood of diagnosis, followed by laboratory evaluation. Laboratory assays include immunoassays as screening tests, such as enzyme-linked immunosorbent assay (ELISA), followed by functional assays like the serotonin release assay (SRA) to confirm the diagnosis.

Treatment strategies aim to inhibit thrombin formation or directly inhibit thrombin. Immediate cessation of heparin, including unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH), as well as any heparin-coated products, is crucial upon suspected or confirmed diagnosis. Alternative anticoagulants must be promptly initiated to prevent or manage HIT-induced thrombosis.

In terms of epidemiology, the United States accounted for approximately 217,000 cases of HIT testing in the Seven Major Markets (7MM) in 2022, representing the largest share among the countries analyzed. The market size attributed to the United States was also the largest among the 7MM countries, capturing around 50% of the total market size in the region in 2022.

There is ongoing investigation into a single therapy, VLX-1005 (Veralox Therapeutics), for the treatment of heparin-induced thrombocytopenia (HIT).

The Heparin-induced Thrombocytopenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Heparin-induced Thrombocytopenia pipeline products will significantly revolutionize the Heparin-induced Thrombocytopenia market dynamics.

Heparin-induced Thrombocytopenia Overview

Heparin-induced thrombocytopenia (HIT) is a serious immune-mediated complication that can occur in patients receiving heparin therapy. Heparin is a commonly used anticoagulant medication, often administered to prevent blood clot formation in various medical conditions such as deep vein thrombosis, pulmonary embolism, and during surgeries involving cardiopulmonary bypass.

HIT typically occurs around 5 to 10 days after initiating heparin therapy, although it can occur earlier with re-exposure to heparin. It is characterized by a paradoxical decrease in platelet count, leading to a heightened risk of thrombosis, rather than the expected anticoagulant effect of heparin. This thrombosis can manifest as deep vein thrombosis, pulmonary embolism, arterial thrombosis, or even skin necrosis.

The pathophysiology of HIT involves the formation of antibodies, typically IgG antibodies, against platelet factor 4 (PF4)–heparin complexes. PF4 is a protein released from platelets upon activation, and heparin can induce the formation of complexes with PF4. In susceptible individuals, these complexes can trigger an immune response, leading to the production of antibodies. These antibodies then bind to PF4-heparin complexes, resulting in platelet activation, aggregation, and consumption, ultimately leading to thrombocytopenia.

There are two main types of HIT: Type I and Type II.

Type I HIT: This is a non-immune mediated form of thrombocytopenia that occurs within the first few days of heparin therapy. It is generally mild and transient, with platelet counts usually returning to normal even with continued heparin use.

Type II HIT: This is the immune-mediated form of thrombocytopenia and is more severe and clinically significant. It typically occurs 5 to 10 days after exposure to heparin. Type II HIT is characterized by the formation of antibodies against PF4-heparin complexes, leading to platelet activation, consumption, and thrombocytopenia. It poses a significant risk of thrombosis, which can lead to serious complications such as stroke, myocardial infarction, or limb ischemia.

Diagnosis of HIT involves clinical assessment, including platelet count monitoring, and laboratory testing to detect HIT antibodies. Serotonin-release assays (SRAs) and enzyme-linked immunosorbent assays (ELISAs) are commonly used for laboratory diagnosis.

Management of HIT involves immediate discontinuation of heparin therapy and initiation of alternative anticoagulation strategies, such as direct thrombin inhibitors (e.g., argatroban, bivalirudin) or fondaparinux, to prevent thrombosis. Close monitoring for thrombotic complications and platelet count recovery is essential. In severe cases or when there is a high risk of thrombosis, additional interventions such as thrombectomy or placement of a vena cava filter may be necessary.

Overall, HIT is a potentially life-threatening complication of heparin therapy that requires prompt recognition and appropriate management to prevent thrombotic complications and ensure patient safety.

Heparin-induced Thrombocytopenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Heparin-induced Thrombocytopenia Epidemiology Segmentation:

The Heparin-induced Thrombocytopenia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Heparin-induced Thrombocytopenia
Prevalent Cases of Heparin-induced Thrombocytopenia by severity
Gender-specific Prevalence of Heparin-induced Thrombocytopenia
Diagnosed Cases of Episodic and Chronic Heparin-induced Thrombocytopenia

Download the report to understand which factors are driving Heparin-induced Thrombocytopenia epidemiology trends @ Heparin-induced Thrombocytopenia Epidemiology Forecast

Heparin-induced Thrombocytopenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Heparin-induced Thrombocytopenia market or expected to get launched during the study period. The analysis covers Heparin-induced Thrombocytopenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Heparin-induced Thrombocytopenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Heparin-induced Thrombocytopenia Therapies

ANGIOMAX
Argatroban

Heparin-induced Thrombocytopenia Key Companies

Veralox Therapeutics
Sandoz
Pfizer Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Fresenius Kabi AG
Dr. Reddy's Laboratories Ltd.
Amphastar Pharmaceuticals Inc.
Aspen Pharmacare Holdings Limited
LEO Pharma A/S
Merck KGaA

Discover more about therapies set to grab major Heparin-induced Thrombocytopenia market share @ Heparin-induced Thrombocytopenia Treatment Landscape

Scope of the Heparin-induced Thrombocytopenia Market Report:

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Heparin-induced Thrombocytopenia Therapies: ANGIOMAX, Argatroban, and others
Heparin-induced Thrombocytopenia Therapeutic Assessment: Heparin-induced Thrombocytopenia current marketed and Heparin-induced Thrombocytopenia emerging therapies

Heparin-induced Thrombocytopenia Market Dynamics: Heparin-induced Thrombocytopenia market drivers and Heparin-induced Thrombocytopenia market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

Heparin-induced Thrombocytopenia Unmet Needs, KOL’s views, Analyst’s views, Heparin-induced Thrombocytopenia Market Access and Reimbursement

Table of Contents

1. Heparin-induced Thrombocytopenia Market Report Introduction
2. Executive Summary for Heparin-induced Thrombocytopenia
3. SWOT analysis of Heparin-induced Thrombocytopenia
4. Heparin-induced Thrombocytopenia Patient Share (%) Overview at a Glance
5. Heparin-induced Thrombocytopenia Market Overview at a Glance
6. Heparin-induced Thrombocytopenia Disease Background and Overview
7. Heparin-induced Thrombocytopenia Epidemiology and Patient Population
8. Country-Specific Patient Population of Heparin-induced Thrombocytopenia
9. Heparin-induced Thrombocytopenia Current Treatment and Medical Practices
10. Heparin-induced Thrombocytopenia Unmet Needs
11. Heparin-induced Thrombocytopenia Emerging Therapies
12. Heparin-induced Thrombocytopenia Market Outlook
13. Country-Wise Heparin-induced Thrombocytopenia Market Analysis (2019–2032)
14. Heparin-induced Thrombocytopenia Market Access and Reimbursement of Therapies
15. Heparin-induced Thrombocytopenia Market Drivers
16. Heparin-induced Thrombocytopenia Market Barriers
17. Heparin-induced Thrombocytopenia Appendix
18. Heparin-induced Thrombocytopenia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Heparin-induced Thrombocytopenia Pipeline

"Heparin-induced Thrombocytopenia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Heparin-induced Thrombocytopenia market. A detailed picture of the Heparin-induced Thrombocytopenia pipeline landscape is provided, which includes the disease overview and Heparin-induced Thrombocytopenia treatment guidelines.

Heparin-induced Thrombocytopenia Epidemiology

DelveInsight's 'Heparin-induced Thrombocytopenia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Heparin-induced Thrombocytopenia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

Kritika Rehani
DelveInsight Business Research LLP
+1 469-945-7679
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

Heparin-induced Thrombocytopenia Market Report 2032: Epidemiology Data, Therapies, Latest Approvals by DelveInsight

Distribution channels: Healthcare & Pharmaceuticals Industry

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.